Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13731114 | 0.82 | MAPT (0.34) | — | |
| SCHEMBL1620237 | 0.81 | CYP3A4 (0.40) | ALOX15ALOX12CYP1A2POLBALDH1A1 | |
| SCHEMBL1620372 | 0.75 | ALOX15 (0.36) | ALOX15ALOX12GAAHTR2ACYP1A2 | |
| SCHEMBL5205295 | 0.73 | CYP1A2 (0.42) | ALOX15ALOX12ERN1GAAHTR2A | |
| SCHEMBL1621332 | 0.72 | GAA (0.54) | ALOX15ALOX12ERN1GAAALDH1A1 | |
| SCHEMBL5549042 | 0.69 | ALOX15 (0.47) | ALOX15ALOX12ERN1GAACYP1A2 | |
| SCHEMBL31500453 | 0.68 | MAPT (0.35) | ERN1GAAHTR2ACYP1A2ALDH1A1 | |
| SCHEMBL26927319 | 0.68 | MAPT (0.35) | ERN1GAAHTR2ACYP1A2ALDH1A1 | |
| SCHEMBL8159871 | 0.68 | ERN1 (0.45) | ALOX15ALOX12ERN1GAAHTR2A | |
| SCHEMBL29937640 | 0.67 | PYCR1 (0.49) | ALOX15ERN1GAAHTR2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194046-B1 | Triazolone derivative | EISAI R&D MAN CO LTD (JP) | 2012-05-09 | — | — | EP | disclosed |
| US-8163787-B2 | Triazolone derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20110112109-A1 | TRIAZOLONE DERIVATIVES | CLARK RICHARD | 2011-05-12 | — | — | US | disclosed |
| US-7928228-B2 | Triazolone derivatives | EISAI CO., LTD. (JP) | 2011-04-19 | — | — | US | disclosed |
| US-7816522-B2 | Triazolone derivatives | EISAI CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-20100190783-A1 | TRIAZOLONE DERIVATIVES | CLARK RICHARD | 2010-07-29 | — | — | US | disclosed |
| EP-2194046-A1 | Triazolone derivative | Eisai R&D Management Co., Ltd. (JP) | 2010-06-09 | — | — | EP | disclosed |
| EP-2000465-A1 | TRIAZOLONE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2008-12-10 | — | — | EP | disclosed |
| US-20080015199-A1 | Triazolone derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190783-A1 | TRIAZOLONE DERIVATIVES | H1-0, H1-10, H1-2 | ALOX15 4635/4885ALOX12 4602/4885ERN1 1354/4885 |
| US-20110112109-A1 | TRIAZOLONE DERIVATIVES | H1-10, H1-0, H1-2 | ALOX15 4625/4885ALOX12 4640/4885ERN1 1512/4885 |
| US-20080015199-A1 | Triazolone derivatives | F3, F12, F2 | ALOX15 2986/4885ALOX12 3190/4885ERN1 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.